Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

PURPOSE: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fujiwara, Yutaka, Toyoda, Masanori, Chayahara, Naoko, Kiyota, Naomi, Shimada, Takanobu, Imamura, Yoshinori, Mukohara, Toru, Minami, Hironobu
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2014
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133207/
https://ncbi.nlm.nih.gov/pubmed/25121773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0104215
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares